HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING VIDEO EDUCATION SERVICES
Zacks Rank    Equity Research    Premium Home    My Account    Help    
Quote:
Login Free Membership
Search:

Analyst Blog  

Walgreen Unveils Flu Impact Report

Share
By: Zacks Equity Research
September 23, 2011 | Comment(s): 0
Recommended this article (6)
WAG | RAD | CVS

Walgreen Co. (WAG - Analyst Report), the largest drugstore chain in the US, recently came up with findings from the first of a two-part Walgreens Flu Impact Report series. The study reveals the impact of flu and related illness on people’s life.

According to the report, the last flu season led to loss of 100 million work days along with $7 billion in lost wages and 32 million missed school days. According to the Centers for Disease Control and Prevention (CDC), approximately 13% of the US population suffers from flu every year, which increases to 20% during the active flu season.

The Walgreens president of pharmacy, health and wellness, Kermit Crawford, stated that immunization rates increased during the last flu season with more than 40% of the total population in the US receiving flu shots. He also believes that the recent report should act as a catalyst to promote the importance of immunization.

Last month, Walgreen had announced the availability of immunization across its 7,700 stores. This also includes all Duane Reade pharmacies in New York and more than 350 Take Care Clinics. The company also informed that flu shots (priced at $31.99 without insurance) will be available daily at its pharmacies for which no appointment would be necessary.

The CDC now recommends flu shots for everyone over six months of age. Moreover, vaccination is now recommended in every season for full protection against influenza. To meet its objective of tapping into the immunization market, Walgreen has more than 27,000 certified immunizing pharmacists lined up.

During the flu season last year, although industry-wide demand for shots was lower than expected, Walgreen continued to grow its market share. The company is undertaking several steps to become a prominent player in the $40 billion total immunization market. Besides the federal government, Walgreen provides maximum flu shot immunizations than any other single entity in the US.

Creating awareness of immunization against flu is common among pharmacies now. Walgreen’s competitor, CVS Caremark Corporation (CVS - Analyst Report) is also set to tackle this year’s flu season with the recently launched “You vs. Flu” campaign, under which seasonal flu vaccinations will be sold through all CVS/pharmacy and MinuteClinic to help consumers fight flu. CVS will charge $29.99 per flu shot and it will also provide a $5 gift card in case any part of the cost remains uncovered by health insurance.

Drugstore chain operator Rite Aid Corp (RAD - Analyst Report) is alsogearing up for the immunization program that is currently underway. The company has trained 11,000 certified immunizing pharmacists to provide vaccinations at every pharmacy. As per latest update (September 22), Rite Aid has given over 364,000 flu immunizations, much higher than the year-ago period. The company is aiming at doubling the number of flu shots this year and has set a target of 1.5 million shots.

We are currently maintaining a long-term Neutral recommendation on Walgreen, in line with CVS Caremark.

Read the full analyst report on WAG

Read the full analyst report on RAD

Read the full analyst report on CVS

 

Please login to Zacks.com or register to post a comment.



Email

Print

Share

Rate Pos

Rate Neg
Attn. Zacks.com Visitors
7 Best Stocks for the Next 30 Days
Get your free Welcome Gifts today*:
 1.  Special Report with best short-term Zacks recommendations from the list that averages a gain of +26% per year
 2.  Our free e-newsletter with 4 "Strong Buy" stocks, Bull & Bear of the Day, and market commentary in every issue.
Get them free right now
  
No cost. Unsubscribe anytime. Privacy Policy
*Only for non-members. May end at any time.

More Zacks Resources

Market Summary May 26, 2012 14:16 pm ET
DJIA 12454.83  -74.92 -0.60%
NASD 2837.53  -1.85 -0.07%
S&P 500 1317.82  -2.86 -0.22%
Partner Center